The current classification criteria for antiphospholipid syndrome (APS) recommend testing for three assays, namely antibodies against cardiolipin (aCL) and β2-glycoprotein I (anti-β2GPI) plus lupus anticoagulant (LA). β2GPIdependent antibodies are those mainly responsible for the positivity in the APS laboratory assays and for most of the pathogenic mechanisms involved in the syndrome. To overcome the technical limitations of APS assays and to identify a broader spectrum of patients, several tests have been assessed as additional laboratory tools: antibodies against domain I of β2GPI, aCL, anti-β2GPI IgA and antibodies against PT are among the most promising but still under evaluation. Other nonclassification/diagnostic autoantibodies have been described in APS, some directly contributing to the clinical manifestations (antibodies against proteins involved in hemostasis, anti-platelet and anti-endothelial cell antibodies) and some others reflecting the ongoing systemic autoimmunity characteristic of the syndrome (anti-nuclear, anti-mitochondrial, anti-red cell, anti-thyroid antibodies, and antibodies against plasma lipoproteins).

Antibodies and Diagnostic Tests in Antiphospholipid Syndrome / C.B. Chighizola, M.O. Borghi, P. Meroni - In: Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects / [a cura di] G. Tsokos. - [s.l] : Elsevier, 2016. - ISBN 9780128019177. - pp. 495-501

Antibodies and Diagnostic Tests in Antiphospholipid Syndrome

C.B. Chighizola
Primo
;
M.O. Borghi
Secondo
;
P. Meroni
Ultimo
2016

Abstract

The current classification criteria for antiphospholipid syndrome (APS) recommend testing for three assays, namely antibodies against cardiolipin (aCL) and β2-glycoprotein I (anti-β2GPI) plus lupus anticoagulant (LA). β2GPIdependent antibodies are those mainly responsible for the positivity in the APS laboratory assays and for most of the pathogenic mechanisms involved in the syndrome. To overcome the technical limitations of APS assays and to identify a broader spectrum of patients, several tests have been assessed as additional laboratory tools: antibodies against domain I of β2GPI, aCL, anti-β2GPI IgA and antibodies against PT are among the most promising but still under evaluation. Other nonclassification/diagnostic autoantibodies have been described in APS, some directly contributing to the clinical manifestations (antibodies against proteins involved in hemostasis, anti-platelet and anti-endothelial cell antibodies) and some others reflecting the ongoing systemic autoimmunity characteristic of the syndrome (anti-nuclear, anti-mitochondrial, anti-red cell, anti-thyroid antibodies, and antibodies against plasma lipoproteins).
Settore MED/16 - Reumatologia
Book Part (author)
File in questo prodotto:
File Dimensione Formato  
TSOKOS_9780128019177 .pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 21.83 MB
Formato Adobe PDF
21.83 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/513059
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact